Enzyme-Triggered Hydrogel for Targeted MMP Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for heart failure, particularly post-myocardial infarction, fail to effectively address left ventricular remodeling and extracellular matrix destruction by matrix metalloproteinases, leading to inadequate treatment outcomes and growing patient populations.
Innovation Solution
Development of biocompatible hydrogels cross-linked with peptide sequences degradable by specific enzymes, containing therapeutic agents like tissue inhibitors of matrix metalloprotease, for targeted delivery to regions with elevated enzyme activity, such as MMP-13, to inhibit proteolytic activity and reduce remodeling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic MMP inhibitors are administered to treat heart failure, then proteolytic activity is inhibited, but adverse reactions increase and therapeutic efficacy is reduced
Solution Approach 1:
The patent applies local quality by designing a hydrogel system that delivers MMP inhibitors specifically to regions of the heart with elevated MMP activity (infarcted and remodeling areas) rather than systemic administration. The hydrogel contains MMP-sensitive peptide crosslinkers that are cleaved by MMPs, triggering localized release of the inhibitor TIMP-2 precisely where needed, thereby reducing off-target effects and adverse reactions while maintaining therapeutic efficacy.
Solution Approach 2:
The hydrogel acts as an intermediary carrier system between the MMP inhibitor and the target tissue. It uses MMP-sensitive peptide crosslinkers as a mediator that responds to the local MMP environment, enabling controlled release of the therapeutic agent only in regions where MMP activity is elevated, thus bridging the gap between systemic delivery and targeted action.
2Adaptability or versatility
If MMP inhibitors are delivered systemically, then proteolytic activity is inhibited throughout the body, but the therapy lacks specificity to regions with elevated MMP activity
Solution Approach 1:
The hydrogel system employs dynamic responsiveness to MMP activity levels. The peptide crosslinkers are designed to be cleaved by MMPs, causing the hydrogel network to dynamically restructure and release the inhibitor in real-time response to the local MMP environment. This dynamic mechanism enables the system to adapt its release profile to the actual MMP activity in different tissue regions, achieving targeted delivery with high regional specificity.
Solution Approach 2:
The system utilizes parameter changes in the hydrogel's physical and chemical properties in response to MMP activity. When MMPs cleave the peptide crosslinkers, the hydrogel's mesh size, swelling ratio, and mechanical properties change, triggering the release of the encapsulated inhibitor. This parameter-based response mechanism ensures that drug release occurs only in regions where MMP activity exceeds a certain threshold, providing spatially selective therapy.
3Ease of operation
If hydrogels with MMP-sensitive peptide crosslinkers are used, then localized release of therapeutic agents is achieved, but the hydrogel structure must be degraded by the target enzyme
Solution Approach 1:
The hydrogel is pre-designed with MMP-sensitive peptide crosslinkers incorporated into its network structure before implantation. This preliminary configuration ensures that the hydrogel remains stable and maintains its structural integrity during storage and initial implantation, while being pre-programmed to degrade and release the therapeutic agent in response to MMP activity. The crosslinker sequences are selected to provide adequate stability under physiological conditions but are specifically susceptible to MMP cleavage when the enzyme is present.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hydrogel system enables localized and controlled release of therapeutic agents, specifically inhibiting matrix metalloproteinases where they are most active, potentially reducing left ventricular remodeling and improving treatment outcomes for heart failure patients.
Implementation Method 1
The hydrogel is cross-linked utilizing a cross-linker comprising a peptide sequence that is capable of being degraded by an enzyme
Data Source
AI summary
The invention relates to compositions comprising (i) biocompatible hydrogel and (ii) one or more therapeutic agents contained within said hydrogel; wherein the hydrogel is cross-linked utilizing a cross-linker comprising a peptide sequence that is capable of being degraded by an enzyme; the therapeutic agent being effective as a treatment of a condition related to the presence of the enzyme.